Pfizer said that Eraxis has been shown to be an effective new agent in the treatment of invasive candidiasis in a Phase III trial involving 47 trial sites in Canada, the US and Europe, of which eight were headed by Canadian researchers.
Bernard Prigent, vice president and medical director, Pfizer Canada, said: “We are very pleased to have the opportunity to develop and bring to patients another important new medicine that is proven to save lives. Pfizer’s role in this R&D demonstrates our commitment to Canadian healthcare by providing the support required to ensure Canadians have access to innovative new medicines.”